A key hurdle in front of the EU reforms to pharma legislation has fallen, after the European Parliament’s Environment, Public Health and Food Safety (ENVI) committee approved a series of ...

With the FDA and EMA releasing their annual reports detailing novel drug approvals in 2024, a new pharmaphorum podcast looks ...

Cambridge, Massachusetts-based Vor Bio has confirmed that it will halt clinical and manufacturing operations, including its ...

For instance, studies have shown that approximately 25% of adults with diabetes reported rationing insulin in the previous ...

The GLISTEN trial of GSK's linerixibat has shown that the oral ileal bile acid transporter (IBAT inhibitor was signposted as ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi ...

Moreover, Downing Street has indicated that the UK will receive "preferential treatment in any further tariffs imposed" as ...

Eli Lilly has backed away from plans to file Alzheimer's drug donanemab in the first quarter of this year, saying the proposal to limit reimbursement of Biogen's first-to-market Aduhelm has made ...

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of ...

Bayer has abandoned development of its investigational P2X3 receptor antagonist eliapixant, despite promising efficacy data in clinical trials, on what appears to be safety grounds. The decision ...

Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in 2023, earning $22.2 billion by 2025, according to new research by GlobalData.

President Donald Trump has withdrawn his nomination of Dave Weldon to lead the CDC, just hours before he was due to appear in front of a Senate confirmation hearing, which has now been cancelled.